Multiple Studies Reinforce Clinical Utility of Oncotype
 

REDWOOD CITY, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced results from multiple studies reinforcing the clinical utility of the company's Oncotype DX(R), a multi-gene expression test to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients. This research was presented at the 30th Annual San Antonio Breast Cancer Symposium, December 13-15.

full article: http://money.cnn.com/news/newsfeeds/...17122007-1.htm